Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Imatinib mesylate is an inhibitor of the receptor tyrosine kinases for platelet-derived
growth factor (PDGF) and stem cell factor (SCF), c-Kit, and inhibits PDGF- and SCF-mediated
cellular events. Docetaxel promotes cell growth arrest by inhibiting the deassembly of
tubulin and by promoting at the same time microtubule assembly. Docetaxel has single agent
activity in ovarian cancer with response rates of 30-40% in the platinum refractory setting.
The combination of imatinib mesylate and docetaxel has potential synergistic effects, based
on previous reports showing synergy in-vitro and in-vivo between PDGFR inhibitors or PI3K
inhibitors and taxane chemotherapy.
This trial will investigate the efficacy the combination of imatinib mesylate and docetaxel
in treating patients with advanced, platinum-refractory ovarian cancer and primary peritoneal
carcinomatosis.
Phase:
Phase 2
Details
Lead Sponsor:
Daniela Matei, MD
Collaborators:
Novartis Pharmaceuticals Sanofi Walther Cancer Institute